Helsinn and the Scientific Centre of Monaco (CSM) have signed a collaboration agreement to support a research project aimed at developing pharmacological inhibitors for the most common form of kidney cancer: clear cell renal cell carcinoma (ccRCC).   ccRCC is diagnosed in over 200,000 patients worldwide each year and the number of people affected continues to increase. The current five year survival rate for stage IV patients is only 10 to 20%.     Studies investigating neuropili...